February 21, 2020
Seeking Alpha
Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail ov... Read more
Bristol Myers Squibb's Competitors, Revenue, Number of Employees, Funding and Acquisitions
Followers on Owler
66,851
Followers on Owler
Based on data from Bristol Myers Squibb's latest SEC filings
Annual Revenue
Based on data from Bristol Myers Squibb's latest SEC filings
Employees
Chairman & CEO
Giovanni Caforio
OVERVIEW
Founded:
1858
Headquarters:
New YorkNew York
Status:
PublicNYSEBMY
Industry Sector:
Pharmaceuticals
Biotechnology
SIC Code:
2834NAICS listing »
2836NAICS listing »
Top Competitors or Alternatives
Missing a competitor? Contribute!
Weigh-in!
Help the Owler community know moreTrending News for Bristol Myers Squibb and Bristol Myers Squibb's Competitors
February 21, 2020
Pharmabiz
Merck receives complete response letter from US FDA for sBLAs for Keytruda six─week dosing schedule
Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Adminis... See more »
February 21, 2020
MarketScreener
Eli Lilly and : Lilly to Participate in Cowen Health Care Conference
(marketscreener.com) INDIANAPOLIS, Feb. 21, 2020 /PRNewswire/ -- Eli Lilly and Company will participa... See more »
Competitive Analysis
TOP COMPETITORS OR ALTERNATIVES
Merck has been one of Bristol Myers Squibb's top competitors. Merck was founded in 1891, and is headquartered in Kenilworth, New Jersey. Merck competes in the Pharmaceuticals industry. Merck generates $21.8B more revenue vs. Bristol Myers Squibb.
RANK
COMPANY
LEADERSHIP
EMPLOYEES
TOTAL FUNDING
REVENUE
Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$24.2B
Bristol Myers Squibb's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 29.1B. Over the last four quarters, Bristol Myers Squibb's revenue has grown by 0.6%. Specifically, in Q3 2019's revenue was $6B; in Q2 2019, it was $6.3B; in Q1 2019, it was $5.9B; in Q4 2018, Bristol Myers Squibb's revenue was $6B.
Acquisitions
COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Celgene Corporation
Jan 2019
Source »$74B
Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.
IFM Therapeutics, LLC
Aug 2017
Source »$300M
IFM is a biopharmaceutical company that develops and commercializes small molecule therapies for the treatment of cancer and inflammatory disorders.
Cormorant Pharmaceuticals
Jul 2016
Source »$500M
Cormorant Pharmaceuticals engages in the research and development of therapeutics for the treatment of cancer and rare diseases.
Padlock Therapeutics, Inc.
Mar 2016
Source »$225M
Padlock Therapeutics researches, discovers, develops and commercializes drugs for protein arginine deiminases.
Cardioxyl Pharmaceuticals, Inc.
Nov 2015
Source »$300M
Cardioxyl Pharmaceuticals engages in the discovery and development of therapies and technologies for the treatment of cardiovascular diseases.
These are all the companies that Bristol Myers Squibb has acquired. Bristol Myers Squibb has acquired 12 companies and its latest acquisition was Celgene Corporation in Jan 2019. Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.
Investments
FOLLOW STATUS
COMPANY
DESCRIPTION
AMOUNT
INVESTMENT DATE
ROUND
EXIT DATE
These are all the companies that Bristol Myers Squibb has invested in. Bristol Myers Squibb has invested 12 companies and its latest investment was Celgene Corporation in Jan 2019. Celgene develops and commercializes novel therapies for the treatment of cancer and inflammatory diseases.
Bristol Myers Squibb News
February 21, 2020PharmaTimes
Opdivo/Yervoy continues to impress in kidney cancer
The results represent the longest follow-up with any immuno-oncology-based therapy in previously untr... See more »
February 20, 2020Globes
Compugen expands agreement with BMS
Israeli drug discovery company Compugen is conducting three cancer treatment trials this year, two of... See more »
February 19, 2020Pharmafile
Opdivo + cabiralizumab combo falls flat in advanced pancreatic cancer
Five Prime Therapeutics and Bristol-Myers Squibb have confirmed that their randomised Phase 2 trial i... See more »
February 14, 2020Zacks
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.... See more »
February 14, 2020pharmaphorum
FDA to fast-track review of BMS' CAR-T, ahead of shareholder deadline
Speculators who bought into a risky three-drug bet are still on track for a payout following Celgene’... See more »
February 13, 2020The Pharma Letter
FDA set a target action date of August 17 for B-MS' lisocabtagene maraleucel
US pharma major Bristol-Myers Squibb today announced that the US Food and Drug Administration has acc... See more »
Bristol Myers Squibb Press Releases
December 7, 2019centralcharts
Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer
The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data a... See more »
December 6, 2019GlobeNewswire
Young Investigators awarded $200k to study how the body's own defense mechanisms may be used in the fight against lung cancer
Two new $200,000 grant-funded studies supported by the Lung Cancer Foundation of America, the Interna... See more »
September 11, 20191888 Press Release
Timothy Kocses, Director, Corporate Technical Accounting, Bristol-Myers Squibb Company to Speak at The Knowledge Group�s The New FASB Lease Accounting Standard
The Knowledge Group, the leading producer of regulatory focused webcasts, has announced today that Ti... See more »
August 26, 2019Business Wire
Bristol-Myers Squibb Announces Agreement Between Celgene and Amgen to Divest OTEZLA® for $13.4 Billion
NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that Celgene Corp... See more »
March 6, 2019streetinsider
Bristol-Myers Squibb to Take Part in the Barclays 2019 Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will take part in a fireside chat at the Barclays 2019 Globa... See more »
February 12, 2019CENTRALCHARTS
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Celgene Corporation - CELG
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti... See more »
January 14, 2019StreetInsider
European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission has approved th... See more »
Bristol Myers Squibb Videos
June 27, 2019Bristol Myers Squibb Youtube Channel
"Strand Therapeutics on its Bristol-Myers Squibb LabCentral Golden Ticket Win" on YOUTUBE
May 12, 2019Bristol Myers Squibb Youtube Channel
"How May Using Biomarkers Help to Understand Rheumatoid Arthritis (RA)?" on YOUTUBE
April 30, 2019Bristol Myers Squibb Youtube Channel
"Cambridge: A Culture of Collaboration" on YOUTUBE
April 4, 2019Bristol Myers Squibb Youtube Channel
"Quality & Compliance | Biologics Careers at Devens, MA | Bristol-Myers Squibb" on YOUTUBE
January 7, 2019Bristol Myers Squibb Youtube Channel
"Inclusion Through the Eyes of Our Leaders" on YOUTUBE
Social Statistics
Headquarters
Trending Companies
IN THE NEWS
Itamar Medical | Builders' General | DuPont | Verdane | MMI | 8VC | Eventus Systems | Mavrik Dental | Chevron | Marriott | Takumi | GE | Vallourec | Sprint | Leidos | Bitcoin | Cubico Sustainable Investments | Fluor | JBS | Ayenda | NeoTX | Preempt, Inc | Sony | HR Path | Audentes Therapeutics | Natrox | Pacific Life Re | UP Education | Vertex | KDC/ONE | Brightstar | Jaguar Land Rover | Reliance | H.I.G. Capital | Ubi Banca | Functional Solutions | Toyota | Ikaria | Udemy | Genentech | Maven | PUSH 7 | Glory4gamers | OnePlus | Flipkart | NIRAS | Idemitsu Kosan | DFS | IMF | Locamodul
PEOPLE ALSO VIEWED
TeaNation | Revel Systems | AlphaSights | Odgers Berndtson | Harvey Norman | Holland Partner Group | Indiegogo | Danone | Ecoluxlite | Republicfamilyofcompanies | Parsons | Viapol | Jitterbit | Freightera | LeanLogistics | DocuSign | NICO | CIGNEX | Roadie | Comscore | The Media Ant | Gaithersburg - Washington Grove Volunteer Fire Department | Seabed Geosolutions | Humtum India | LiveCareer | Foremost Farms USA | CWFI | Dailycred | Al Aydi Tent & Metal | ClearScore
Summary
ABOUT
Overview
Bristol-Myers Squibb is a biopharmaceutical firm that discovers, develops and delivers medicines for patients prevail over serious diseases. Bristol Myers Squibb was founded in 1858. Bristol Myers Squibb's headquarters is located in New York, New York...
CEO
Bristol Myers Squibb's Chairman & CEO, Giovanni Caforio, currently has an approval rating of 78%. Bristol Myers Squibb's primary competitors are Merck, Roche & Gilead.Website
bms.comFrequently Asked Questions about Bristol Myers Squibb
When was Bristol Myers Squibb founded?
Bristol Myers Squibb was founded in 1858Who is Bristol Myers Squibb's CEO?
Bristol Myers Squibb's CEO is Giovanni CaforioHow much revenue does Bristol Myers Squibb generate?
Bristol Myers Squibb generates $24.2B in revenueHow much funding does Bristol Myers Squibb have?
Bristol Myers Squibb has historically raised $0 in fundingWhere is Bristol Myers Squibb's headquarters?
Bristol Myers Squibb's headquarters is in New York New York, USA
How many employees does Bristol Myers Squibb have?
Bristol Myers Squibb has 23,300 employeesWhat sector does Bristol Myers Squibb operate in?
Bristol Myers Squibb is in Pharmaceuticals, BiotechnologyWho are Bristol Myers Squibb's competitors?
Bristol Myers Squibb's top competitors are Merck, Roche, GileadWho has Bristol Myers Squibb invested in?
Bristol Myers Squibb's has invested in companies such as GNS Healthcare, PathAI, Vedanta
